Exploring the Gut-Brain Axis in Ageing and Neurodegeneration
Role of the Gut-microbiota on Ageing and Neurodegeneration: a Clinical and Brain Imaging Study
IRCCS San Camillo, Venezia, Italy
200 participants
May 1, 2023
OBSERVATIONAL
Conditions
Summary
Neurodegenerative diseases are a major health concern due to their growing societal implications and economic costs. The identification of early markers of pathogenic mechanisms is one of the current main challenges. The gut-brain axis has become a primary target because of its transversal role across the neurodegenerative spectrum and its effect on cognition. However, despite recent progress, how changes in the gut-microbiota composition can affect the human brain is still unclear. The goal of this observational study is to characterise the gut-microbiota composition associated with alterations in brain structure and function during the ageing process and across neurodegenerative disorders. This is based on recent studies showing that changes in the human brain and in the microbiota composition, can indicate very sensitively and in a predictive way pathological development and, consequently, be used as markers of neurodegenerative diseases. The main questions it aims to answer are: * How variation in the gut-microbiota composition correlates with the normal brain ageing trajectory? * How dysregulation in the gut-microbiota correlates with pathological changes in brain regions in specific neurodegenerative disorders? * Can the impact of the gut-microbiota on the brain be modulated by blood biomarkers? The investigators will recruit 40 young healthy participants, 40 old healthy participants, 40 participants with prodromal Alzheimer's Disease, 40 participants with Parkinson's Disease and 40 participants with Multiple Sclerosis. Participants will undergo the following examinations: * Magnetic Resonance Imaging * Analysis of a stool sample * Analysis of a blood sample * Neuropsychological assessment * Questionnaires on eating habits
Eligibility
Inclusion Criteria20
- Healthy Young and Old Subjects:
- or 60-90 years old
- Cognitively healthy (Mini-Mental State examination ≥ 26)
- Absence of significant neurological disorders
- Patients with prodromal Alzheimer's Disease:
- Subjective cognitive complaint (corroborated by the informant)
- Episodic memory deficit on neuropsychological testing
- Clinical Dementia Rating = 0.5
- Mini-Mental State Examination (MMSE) \> 23
- Independently functioning in activities of daily living
- Patients with Parkinson's Disease:
- Recent diagnosis of Parkinson's Disease
- Mild-moderate score at the Unified Parkinson's Disease Rating Scale (UPDRS)
- Cognitively healthy (Mini-Mental State examination ≥ 26)
- In case of taking medications for Parkinson's Disease: stable dosage for at least 6 months
- Patients with Multiple Sclerosis:
- Recent diagnosis of relapsing-remitting Multiple Sclerosis
- Expanded Disability Status Scale score ≤ 4.0
- Cognitively healthy (Mini-Mental State examination ≥ 26)
- In case of taking medications for Multiple Sclerosis: stable dosage for at least 6 months.
Exclusion Criteria4
- For both healthy participants and patients:
- Contraindications to magnetic resonance imaging (metal implant in body, known claustrophobia, pacemakers)
- Severe comorbidities
- Antibiotics treatments over the last 3 months
Interventions
The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
Information on eating habits will be derived from food questionnaires.
The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).
Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.
The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05934188